Immunotherapy and targeted therapy for cervical cancer: an update
Menderes G, Black J, Schwab CL, Santin AD. Immunotherapy and targeted therapy for cervical cancer: an update. Expert Review Of Anticancer Therapy 2015, 16: 83-98. PMID: 26568261, DOI: 10.1586/14737140.2016.1121108.Peer-Reviewed Original ResearchConceptsCervical cancer patientsCervical cancerCancer patientsImmune check pointsUse of immunotherapyMetastatic cervical cancerPrognosis of patientsActionable driver mutationsTyrosine kinase inhibitorsImmune system interactionsImmunotherapy studiesMedian survivalAngiogenesis inhibitorsChemotherapeutic drugsPatientsDriver mutationsKinase inhibitorsNew therapeuticsCancerNext-generation sequencingImmunotherapyTherapyGeneration sequencingInhibitorsPrognosisWeekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review
Roque DM, Ratner ES, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Nelson WK, Santin AD. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review. Gynecologic Oncology 2015, 137: 392-400. PMID: 25792179, DOI: 10.1016/j.ygyno.2015.03.008.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabDisease-Free SurvivalDrug Administration ScheduleEpothilonesFallopian Tube NeoplasmsFemaleHumansMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsPeritoneal NeoplasmsProspective StudiesRetrospective StudiesConceptsObjective response rateFallopian tube cancerWeekly ixabepiloneOvarian cancerConcurrent bevacizumabRetrospective reviewMedian PFS/OSSimilar objective response ratesWarrants further prospective studySingle-institution retrospective reviewCA-125 criteriaPFS/OSTreatment of recurrentKaplan-Meier methodFurther prospective studiesBiweekly bevacizumabMedian PFSAcceptable toxicityGrade 1/2Median durationOverall survivalPrior linesClinical outcomesProspective studyUterine cancer